Semax Dosage: Russian Clinical Use vs US Status
Last updated September 27, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← Semax encyclopedia entry · See also: Selank dosage · Regulatory tracker
Semax is a genuine approved medicine in Russia (it is on the Russian list of vital and essential drugs), developed at the Institute of Molecular Genetics. But it has never been FDA-approved, and in the US it circulates as an unregulated research chemical; since April 2026 FDA's 503A list names it in no category, so pharmacies cannot compound it. The dosing below reflects Russian clinical and community practice — it is documented for education, not offered as instructions for US self-use.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
The short version
Semax is a short peptide derived from the ACTH(4-10) fragment, used intranasally and studied mainly in Russia as a nootropic and neuroprotective agent — including in stroke and cognitive contexts. Its dosing story is unusual on this site because, unlike the purely research-grade peptides, Semax actually has a regulated clinical history — just not in the US. That makes the honest framing "approved there, unapproved here," and it changes what a "dose" means depending on where you are.
Intranasal dosing as reported
Russian clinical and community sources most commonly describe intranasal administration in the following range. These are descriptive, and US-sourced product is not the regulated Russian medicine.
Community-reported. Amounts users report, recorded for education. Not a recommendation, and not a dose any study has shown to be safe or effective.
| Parameter | Commonly reported |
|---|---|
| Amount | ~250–600 mcg per dose |
| Frequency | 2–3× daily |
| Route | Intranasal (drops/spray) |
| Form | Often a percentage solution (e.g. 0.1%) |
The intranasal route is used because peptides are poorly absorbed orally; nasal delivery also offers a potential route toward the central nervous system. Russian products are sold as "0.1%" and "1%" nasal drops, and the two are not interchangeable: a 1% solution holds 10 mg of semax per millilitre and a 0.1% solution holds 1 mg, a tenfold difference in every drop. The human studies on the semax entry used the 1% solution (brain imaging in healthy volunteers in 2018, and peptic ulcers) or courses of 6 to 18 mg a day in stroke and motor neuron disease; the 250–600 mcg figure above is the smaller amount reported in circulation, not a dose any of those studies tested.
The US picture and its risks
In the US, Semax is not an approved drug and is not recognized as a dietary supplement, so it reaches users through research-chemical vendors or compounding pharmacies. That introduces the familiar problems of an unregulated product — unverified identity, purity, and dose — and the FDA has specifically raised immunogenicity concerns about compounded peptides (the risk that impurities provoke an immune response). For reconstituted nasal solutions there is the added issue of sterility, since nasal mucosa is sensitive to contamination. See the Regulatory Status Tracker for how foreign-approved peptides are treated in the US.
Frequently asked questions
Is Semax a banned substance in sport?
Semax is not named on WADA's 2026 or 2027 Prohibited List, and because it is approved in Russia, whether S0 applies is unsettled: ask Global DRO before competing.
Is it the same as Selank?
No — they are different peptides from the same Russian program. Semax is framed as pro-cognitive/neurotrophic, Selank as anxiolytic. See the Selank dosage page.
Can a US doctor prescribe it?
It is not an FDA-approved product, so it is not a prescription item. Since April 2026 FDA's 503A list names it in no category, so pharmacies cannot compound it either (as of September 27, 2026); what is sold in the US is an unregulated research chemical.
Sources
- Russian Federation List of Vital and Essential Drugs (Semax listed); Institute of Molecular Genetics, Russian Academy of Sciences.
- Dolotov OV, et al. Semax and BDNF / neurotrophin signaling. Brain Res.
- U.S. FDA — Drugs@FDA database (no Semax approval); FDA statements on compounded-peptide immunogenicity.
Medical disclaimer: Education only, not medical advice. Semax is not FDA approved; US-sourced product is unregulated. Dosing figures reflect Russian clinical/community practice, not a recommendation. Consult a licensed clinician.